GB13 Clinical Trial Presented at International Conference

A poster presentation, entitled LOCO-REGIONAL INFUSION OF GB-13 (IL13.E13K-PE4E) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT HIGH-GRADE GLIOMA is presented at the SNO 2022 Annual Clinical Trials and Brain Metastases Conference held in Toronto CA from August 12-13. The poster includes a Phase 1 clinical trial design for the treatment GBM and pediatric DMG with GB13 with CED administration. Dr Randy Schrecengost, CSO at Targepeutics is a contributing author on the poster. The abstract is published in Neuro-Oncology Advances August Vol 4 Issue Supplement and can be accessed here.